Timolol

Timolol

SCHEMBL4912

CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2

The experimentally established mechanism targets of Timolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 1/20 1.00
ADRB1 known ✓ P08588 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
HTR1A P08908 1/20 1.00
CYP2D6 P10635 1/20 1.00
ADRB3 P13945 1/20 1.00
NFKB1 P19838 1/20 1.00
DRD1 P21728 1/20 1.00
SIGMAR1 Q99720 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
SMN1; SMN2 Q16637 1/20 0.85
BLM P54132 1/20 0.85
ALDH1A1 P00352 5/20 0.52
ALOX15 P16050 2/20 0.52
HSD17B10 Q99714 2/20 0.52
MAPT P10636 2/20 0.52
HPGD P15428 2/20 0.52
KDM4E B2RXH2 1/20 0.52
KMT2A Q03164 5/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Timolol SCHEMBL2553603 1.00 CYP1A2 (1.00) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL1587691 1.00 CYP1A2 (1.00) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL222970 1.00 CYP1A2 (1.00) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL8858736 0.99 CYP1A2 (0.98) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL5539013 0.99 CYP1A2 (0.98) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL11418545 0.99 CYP1A2 (0.98) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL16094075 0.99 CYP1A2 (0.98) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL2356059 0.99 CYP1A2 (0.98) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL7591293 0.99 CYP1A2 (0.98) CYP1A2ADRB2ADRB1CYP3A4HTR1A
Timolol SCHEMBL8858730 0.99 CYP1A2 (0.98) CYP1A2ADRB2ADRB1CYP3A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 48978 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6335335-B1 None US claimed
US-20260137558-A1 OPHTHALMIC DEVICE Able Tx Ltd. (IL) 2026-05-21 US claimed
WO-2026102187-A1 ENGINEERED VIRUS-LIKE PARTICLES COMPRISING A BASE EDITOR FOR THE TREATMENT OF GLAUCOMA, AND APPLICATIONS THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-15 WO claimed
EP-4739302-A2 HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS Cella Therapeutics, LLC (US) 2026-05-13 EP claimed
EP-3854885-B1 PHARMACOGENOMIC SCREENING METHOD FOR ANTICIPATING A PATIENT'S RESPONSE TO THE TREATMENT OF OCULAR HYPERTENSION CANUT JORDANA MARIA ISABEL (ES) 2026-05-06 EP claimed
WO-2026090164-A1 COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN KALLYOPE, INC. (US) 2026-04-30 WO claimed
US-20260108493-A1 COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND CAAMTECH, INC. (US) 2026-04-23 US claimed
EP-3973954-B1 PRESERVATIVE FREE PHARMACEUTICAL COMPOSITIONS FOR OPHTHALMIC ADMINISTRATION NTC S R L (IT) 2026-04-22 EP claimed
EP-4727545-A2 COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS Neurawell Therapeutics (US) 2026-04-22 EP claimed
EP-4724839-A2 CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS Mediprint Ophthalmics Inc. (US) 2026-04-15 EP claimed
EP-0036351-A2 Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1981-09-23 EP claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
EP-0036138-A2 Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide MERCK & CO. INC. (US) 1981-09-23 EP claimed
EP-0033042-A1 Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors MERCK & CO. INC. (US) 1981-08-05 EP claimed
US-4281654-A Drug delivery system for controlled ocular therapy ALZA CORPORATION (US) 1981-08-04 US claimed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP claimed
US-4256108-A Microporous-semipermeable laminated osmotic system ALZA CORPORATION (US) 1981-03-17 US claimed
US-4247550-A Compositions and methods for the treatment of hypertension or oedemas LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 1981-01-27 US claimed
EP-0014642-A2 Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure MERCK & CO. INC. (US) 1980-08-20 EP claimed
EP-0012401-A1 Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them MERCK & CO. INC. (US) 1980-06-25 EP claimed